Survival in women with grade 1 serous ovarian carcinoma.

Amanda Nickles Fader, James Java, Stefanie Ueda, Robert Bristow, Deborah K. Armstrong, Michael A. Bookman, David M. Gershenson, Oncology Group (GOG) Gynecologic Oncology Group (GOG)

Research output: Contribution to journalArticlepeer-review

Abstract

To examine clinicopathologic variables associated with survival among women with low-grade (grade 1) serous ovarian carcinoma enrolled in a phase III study. This was an ancillary data analysis of Gynecologic Oncology Group protocol 182, a phase III study of women with stage III-IV epithelial ovarian carcinoma treated with carboplatin and paclitaxel compared with triplet or sequential doublet regimens. Women with grade 1 serous carcinoma (a surrogate for low-grade serous disease) were included in the analysis. Among the 3,686 enrolled participants, 189 had grade 1 disease. The median age was 56.5 years and 87.3% had stage III disease. The median follow-up time was 47.1 months. Stratification according to residual disease after primary surgery was microscopic residual in 24.9%, 0.1-1.0 cm of residual in 51.3%, and more than 1.0 cm of residual in 23.8%. On multivariate analysis, only residual disease status (P=.006) was significantly associated with survival. Patients with microscopic residual had a significantly longer median progression-free (33.2 months) and overall survival (96.9 months) compared with those with residual 0.1-1.0 cm (14.7 months and 44.5 months, respectively) and more than 1.0 cm of residual disease (14.1 months and 42.0 months, respectively; progression-free and overall survival, P<.001). After adjustment for other variables, patients with low-grade serous carcinoma with measurable residual disease had a similar adjusted hazard ratio for death (2.12; P=.002) as their high-grade serous carcinoma counterparts with measurable disease (2.31; P<.001). Surgical cytoreduction to microscopic residual was associated with improved progression-free and overall survival in women with advanced-stage low-grade serous ovarian carcinoma. ClinicalTrials.gov, www.clinicaltrials.gov, NCT00011986. II.

Original languageEnglish (US)
Pages (from-to)225-232
Number of pages8
JournalUnknown Journal
Volume122
Issue number2 Pt 1
StatePublished - Aug 2013

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Survival in women with grade 1 serous ovarian carcinoma.'. Together they form a unique fingerprint.

Cite this